menu search

Zyversa therapeutics announces publication in molecular neurobiology reinforcing data demonstrating that inflammasome asc inhibitor ic 100 attenuates the inflammatory response causing neuronal damage

Molecular Neurobiology publication demonstrated that NLRP3 inflammasomes have an important role in the pathoge...

November 1, 2023, 12:07 pm

Orgenesis announces withdrawal of proposed public offering

GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Or...

October 31, 2023, 1:30 am

Gemini seeking $1.6bn grayscale bitcoin trust pound of flesh from genesis

This trust currently holds a value of approximately $1.6bn. In the filed lawsuit, Gemini petitions the court to cast a ruling stating ...

October 30, 2023, 9:14 am

Sbf takes the stand, ‘buy bitcoin’ searches soar and other news: hodler’s digest, oct. 22-28

Sam Bankman-Fried testifies in court, searches for ‘buy Bitcoin’ surge, and Gemini sues genesis ove...

October 28, 2023, 10:14 pm

Pyrogenesis canada to voluntarily delist shares from nasdaq

Pyrogenesis Canada Inc announced that it intends to voluntarily delist its common shares from the Nasd...

October 27, 2023, 9:31 am

Pyrogenesis wins c$360,000 contract for plasma-based system for chemical warfare waste destruction

Pyrogenesis Canada Inc. (TSX:PYR, NASDAQ:PYR) announced it has secured an initial contract from a Europ...

October 24, 2023, 9:03 am

Repeat: prairie operating co. submits initial permit application with the colorado energy & carbon management commission

HOUSTON, Oct. 20, 2023 (GLOBE NEWSWIRE) — Prairie Operating Co. (OTCQB: CRKR; the “Company”), is pleased to announce that it has submitted its i...

October 20, 2023, 9:03 pm

Four genesis-affiliated skilled nursing facilities recognized by newsweek as one of america’s best nursing homes for 2024

KENNETT SQUARE, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) — Today, genesis HealthCare announced that four o...

October 19, 2023, 4:41 pm

Ny attorney general sues gemini, genesis, and dcg for alleged billion-dollar fraud

New York Attorney General Letitia James has initiated a lawsuit against prominent cryptocurrency companies, including Gemini Trust Company (Gemini), <...

October 19, 2023, 12:14 pm

Preclinical data demonstrate anti-siglec-15 treatment reduced bone loss and enhanced bone quality in mice with moderate-to-severe osteogenesis imperfecta (oi)

Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting BELTSVILLE, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) — N...

October 17, 2023, 12:05 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm


Search within

Pages Search Results: